» Articles » PMID: 25564516

Lysine Demethylase KDM4A Associates with Translation Machinery and Regulates Protein Synthesis

Overview
Journal Cancer Discov
Specialty Oncology
Date 2015 Jan 8
PMID 25564516
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Chromatin-modifying enzymes are predominantly nuclear; however, these factors are also localized to the cytoplasm, and very little is known about their role in this compartment. In this report, we reveal a non-chromatin-linked role for the lysine-specific demethylase KDM4A. We demonstrate that KDM4A interacts with the translation initiation complex and affects the distribution of translation initiation factors within polysome fractions. Furthermore, KDM4A depletion reduced protein synthesis and enhanced the protein synthesis suppression observed with mTOR inhibitors, which paralleled an increased sensitivity to these drugs. Finally, we demonstrate that JIB-04, a JmjC demethylase inhibitor, suppresses translation initiation and enhances mTOR inhibitor sensitivity. These data highlight an unexpected cytoplasmic role for KDM4A in regulating protein synthesis and suggest novel potential therapeutic applications for this class of enzyme.

Significance: This report documents an unexpected cytoplasmic role for the lysine demethylase KDM4A. We demonstrate that KDM4A interacts with the translation initiation machinery, regulates protein synthesis and, upon coinhibition with mTOR inhibitors, enhances the translation suppression and cell sensitivity to these therapeutics.

Citing Articles

Analogue-Sensitive Inhibition of Histone Demethylases Uncovers Member-Specific Function in Ribosomal Protein Synthesis.

Kuwik J, Scott V, Chedid S, Stransky S, Hinkelman K, Kavoosi S J Am Chem Soc. 2025; 147(4):3341-3352.

PMID: 39808475 PMC: 11783601. DOI: 10.1021/jacs.4c13870.


Versatile JMJD proteins: juggling histones and much more.

Oh S, Janknecht R Trends Biochem Sci. 2024; 49(9):804-818.

PMID: 38926050 PMC: 11380596. DOI: 10.1016/j.tibs.2024.06.009.


Epigenetic modulators provide a path to understanding disease and therapeutic opportunity.

Honer M, Ferman B, Gray Z, Bondarenko E, Whetstine J Genes Dev. 2024; 38(11-12):473-503.

PMID: 38914477 PMC: 11293403. DOI: 10.1101/gad.351444.123.


Histone lysine demethylase 4 family proteins maintain the transcriptional program and adrenergic cellular state of MYCN-amplified neuroblastoma.

Abu-Zaid A, Fang J, Jin H, Singh S, Pichavaram P, Wu Q Cell Rep Med. 2024; 5(3):101468.

PMID: 38508144 PMC: 10983111. DOI: 10.1016/j.xcrm.2024.101468.


Oncogenic Cells of Renal Embryonic Lineage Sensitive to the Small-Molecule Inhibitor QC6352 Display Depletion of KDM4 Levels and Disruption of Ribosome Biogenesis.

Pichavaram P, Jablonowski C, Fang J, Fleming A, Gil H, Boghossian A Mol Cancer Ther. 2023; 23(4):478-491.

PMID: 37988559 PMC: 10987284. DOI: 10.1158/1535-7163.MCT-23-0312.


References
1.
Vistejnova L, Dvorakova J, Hasova M, Muthny T, Velebny V, Soucek K . The comparison of impedance-based method of cell proliferation monitoring with commonly used metabolic-based techniques. Neuro Endocrinol Lett. 2009; 30 Suppl 1:121-7. View

2.
Mabuchi S, Hisamatsu T, Kimura T . Targeting mTOR signaling pathway in ovarian cancer. Curr Med Chem. 2011; 18(19):2960-8. DOI: 10.2174/092986711796150450. View

3.
Ciruelos Gil E . Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treat Rev. 2014; 40(7):862-71. DOI: 10.1016/j.ctrv.2014.03.004. View

4.
Roberts P, Usary J, Darr D, Dillon P, Pfefferle A, Whittle M . Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clin Cancer Res. 2012; 18(19):5290-303. PMC: 3715399. DOI: 10.1158/1078-0432.CCR-12-0563. View

5.
Donlin L, Andresen C, Just S, Rudensky E, Pappas C, Kruger M . Smyd2 controls cytoplasmic lysine methylation of Hsp90 and myofilament organization. Genes Dev. 2012; 26(2):114-9. PMC: 3273835. DOI: 10.1101/gad.177758.111. View